Lexeo Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $654,000 | — |
| Research and development | $63.8M | $74.1M | $53.1M | $49.2M | — |
| Operating expenses | $109.3M | $105.8M | $68.5M | $61.2M | — |
| Operating income | -$109.3M | -$105.8M | -$68.5M | -$60.5M | — |
| Interest expense | $95,000 | $137,000 | $205,000 | $91,000 | — |
| Pretax income | -$99.7M | -$98.4M | -$66.4M | -$59.3M | — |
| Income tax expense | $0 | $0 | — | — | — |
| Net income | -$100.0M | -$98.3M | -$66.4M | -$59.3M | — |
| Balance Sheet | |||||
| Cash and equivalents | $63.0M | $35.0M | $121.5M | $77.3M | $135.9M |
| Current assets | $188.4M | $126.1M | $124.3M | $80.0M | — |
| Total assets | $268.7M | $146.9M | $139.8M | $97.1M | — |
| Current liabilities | $16.8M | $22.8M | $17.2M | $14.3M | — |
| Total liabilities | $22.0M | $30.1M | $26.3M | $25.0M | — |
| Stockholders' equity | $246.7M | $116.8M | $113.5M | -$113.0M | -$55.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$98.6M | -$81.2M | -$59.5M | -$54.6M | — |
| Depreciation and amortization | $268,000 | $304,000 | $271,000 | $120,000 | — |
| Stock-based compensation | $12.1M | $12.5M | $3.0M | $1.8M | — |
| Capital expenditure | $397,000 | $481,000 | $115,000 | $672,000 | — |
| Free cash flow | -$99.0M | -$81.6M | -$59.6M | -$55.2M | — |
| Share repurchases | — | $17,000 | — | — | — |
Shares outstanding 78.5M · Free float 98.8%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.